Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|July 7, 2016

BioOutsource Launches IgG Glycosylation Tool

The assay will provide information on biosimilar comparability.

Sartorius Stedim subsidiary BioOutsource announced on July 7, 2016 that it is launching a new biosimilarity comparability tool to measure IgG glycosylation. The tool incorporates a collection of orthogonal methods, including analysis by CD16a (FcγRIIIa), surface plasmon resonance spectroscopy for ligand binding, and antibody-dependent cell-mediated cytotoxicity (ADCC) functional assays.

The tool will generate information on the molecular structure of a drug as well as its key mechanism of action, allowing scientists to accurately characterize their investigational biosimilar molecule and identify glycosylation patterns.

“The structural classification and monosaccharide composition of carbohydrates attached to the constant region of therapeutic biosimilar antibodies is key to their binding,” said Daniel Galbraith, CSO at Sartorius Stedim BioOutsource, in a press release. “An accurate understanding of these glycans ensures effective selection of biosimilars that have the optimum ADCC activity to destroy tumor cells.”

Source: Sartorius Stedim BioOutsource


Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.